Back Bay Life Science Advisors Senior Vice President, Michelle Hoffmann, wrote a piece for STAT’s “first opinion” section on the U.S. biosimilar market. Titled, “Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?” the piece explains the history of U.S. biosimilars and details what the future may hold.
By: Greg Benning
Back Bay Insights on JP Morgan 2018 Market Outlook; Inflection Point Investing
JP Morgan’s recently published Eye on the Market Outlook 2018 The Decline of Western Centralization, is a cleverly-titled economic research piece focused on the implications of unwinding a 9-year, $11 trillion central bank stimulus effort. Read more »
Back Bay Life Science Advisors CEO Jonathan Gertler spoke with FierceCEO about growth, innovation and the joy of simultaneously leading and working for great people.
In “Back Bay Life Science Advisors CEO Jonathan Gertler helps healthcare companies grow,” Gertler describes Back Bay’s role in advancing new healthcare technologies to help life science companies improve.
Back Bay Life Science Advisors (Back Bay) will again join biotech leaders at the BioNetwork West Partnering Summit this October. The summit brings together leaders from top life science organizations to discuss top trends in business development and highlight new technologies and innovations. For the third year, Back Bay will provide lead sponsorship for the event. Read more »
Leaders in life sciences and corporate law gather in Copenhagen on 10 October for to share and discuss best practices on sustaining thriving biotechs in the Nordic countries
Dr. Stephan Gauldie was recently interviewed by PharmaVOICE on drug-device combination development, where he discussed some of the challenges that companies face, and their need to understand the critical factors of a drug-device combination when it comes to a regulatory review.